Related Experiment Video
Updated: Mar 28, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
DNA copy number gains in malignant pleural mesothelioma
Masashi Furukawa1, Shinichi Toyooka2, Tatsuro Hayashi3
1Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700-8558, Japan.
Abstract:
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with an extremely poor prognosis. The incidence of MPM is increasing as a result of widespread exposure to asbestos. The molecular pathogenesis of MPM remains unclear. The present study analyzed the frequency of various genomic copy number gains (CNGs) in MPM using reverse transcription-quantitative polymerase chain reaction. A total of 83 primary MPMs and 53 primary lung adenocarcinomas were analyzed to compare the CNGs of EGFR, KRAS, MET, FGFR1 and SOX2. In MPM, the CNGs of EGFR, KRAS, MET, FGFR1 and SOX2 were detected in 12 (14.5%), 8 (9.6%), 5 (6.0%), 4 (4.8%) and 1 (1.2%) of the samples, respectively. In lung adenocarcinomas, the CNGs of EGFR, KRAS, MET, FGFR1 and SOX2 were detected in 21 (39.6%), 12 (22.6%), 5 (9.4%), 10 (18.9%) and 0 (0.0%) of the samples, respectively. The CNGs of EGFR, KRAS and FGFR1 were significantly less frequent in the MPMs compared with the lung adenocarcinomas (P=0.0018, 0.048 and 0.018, respectively). Overall, the MPMs exhibited these CNGs less frequently compared with the lung adenocarcinomas (P=0.0002). The differences in CNGs between the two tumor types suggested that they are genetically different.
Insights
Malignant pleural mesothelioma (MPM) shows fewer genomic copy number gains in key genes like EGFR and KRAS compared to lung adenocarcinoma. These genetic differences highlight distinct molecular pathways in these aggressive cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer with increasing incidence due to asbestos exposure.
- The molecular underpinnings of MPM pathogenesis are not well understood.
- Genomic alterations are crucial in cancer development and progression.
Purpose of the Study:
- To investigate and compare the frequency of specific genomic copy number gains (CNGs) in MPM and lung adenocarcinoma.
- To identify potential genetic distinctions between MPM and lung adenocarcinoma.
Main Methods:
- Utilized reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to analyze CNGs.
- Examined 83 primary MPMs and 53 primary lung adenocarcinomas.
- Assessed CNGs for EGFR, KRAS, MET, FGFR1, and SOX2 genes.
Main Results:
- Significantly lower frequencies of CNGs for EGFR, KRAS, and FGFR1 were observed in MPM compared to lung adenocarcinoma.
- Overall, MPM samples exhibited fewer CNGs across the studied genes than lung adenocarcinoma samples (P=0.0002).
- Specific frequencies for CNGs in MPM were: EGFR (14.5%), KRAS (9.6%), MET (6.0%), FGFR1 (4.8%), SOX2 (1.2%).
Conclusions:
- MPM and lung adenocarcinoma demonstrate significant genetic differences in terms of specific genomic copy number gains.
- These findings contribute to understanding the distinct molecular profiles of these two thoracic malignancies.
Related Concept Videos
Abnormal Proliferation
Cancers Originate from Somatic Mutations in a Single Cell
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...

